1. Home
  2. WKHS vs MAIA Comparison

WKHS vs MAIA Comparison

Compare WKHS & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Workhorse Group Inc.

WKHS

Workhorse Group Inc.

HOLD

Current Price

$3.03

Market Cap

33.7M

ML Signal

HOLD

Logo MAIA Biotechnology Inc.

MAIA

MAIA Biotechnology Inc.

HOLD

Current Price

$1.34

Market Cap

79.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WKHS
MAIA
Founded
2007
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Auto Manufacturing
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
33.7M
79.0M
IPO Year
2008
2022

Fundamental Metrics

Financial Performance
Metric
WKHS
MAIA
Price
$3.03
$1.34
Analyst Decision
Hold
Analyst Count
1
0
Target Price
$21.00
N/A
AVG Volume (30 Days)
97.8K
539.1K
Earning Date
05-14-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
86.92
33.33
EPS
N/A
N/A
Revenue
$763,173.00
N/A
Revenue This Year
$89.23
N/A
Revenue Next Year
$28.84
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.53
$0.87
52 Week High
$11.80
$3.19

Technical Indicators

Market Signals
Indicator
WKHS
MAIA
Relative Strength Index (RSI) 48.92 46.30
Support Level $2.89 $1.25
Resistance Level $3.56 $1.48
Average True Range (ATR) 0.17 0.07
MACD -0.02 -0.00
Stochastic Oscillator 22.34 26.32

Price Performance

Historical Comparison
WKHS
MAIA

About WKHS Workhorse Group Inc.

Workhorse Group Inc is a technology company with a vision to pioneer the transition to zero-emission commercial vehicles. Its focus is to provide sustainable and cost-effective solutions to the commercial transportation sector. It designs and manufactures all-electric vehicles, including the technology that optimizes the way these vehicles operate. It's focused on a core competency of bringing electric delivery vehicle platforms to serve the last-mile delivery market. Its products are marketed under the Workhorse brand.

About MAIA MAIA Biotechnology Inc.

MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of targeted immunotherapies for cancer, with an initial focus on non-small cell lung cancer (NSCLC), which represents the majority of lung cancer cases. Its asset, ateganosine (THIO, also known as 6-thio-dG or 6-thio-deoxyguanosine), is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The treatment approach involves administering THIO followed by the immune checkpoint inhibitor Libtayo (cemiplimab), which is manufactured and commercialized by Regeneron.

Share on Social Networks: